134 related articles for article (PubMed ID: 9662602)
1. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro.
Dearling JL; Lewis JS; Mullen GE; Rae MT; Zweit J; Blower PJ
Eur J Nucl Med; 1998 Jul; 25(7):788-92. PubMed ID: 9662602
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of copper radiopharmaceuticals with mixed bis(thiosemicarbazone) ligands.
Ackerman LJ; West DX; Mathias CJ; Green MA
Nucl Med Biol; 1999 Jul; 26(5):551-4. PubMed ID: 10473194
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia.
Bonnitcha PD; Vāvere AL; Lewis JS; Dilworth JR
J Med Chem; 2008 May; 51(10):2985-91. PubMed ID: 18416544
[TBL] [Abstract][Full Text] [Related]
4. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.
McQuade P; Martin KE; Castle TC; Went MJ; Blower PJ; Welch MJ; Lewis JS
Nucl Med Biol; 2005 Feb; 32(2):147-56. PubMed ID: 15721760
[TBL] [Abstract][Full Text] [Related]
5. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships.
Dearling JL; Lewis JS; Mullen GE; Welch MJ; Blower PJ
J Biol Inorg Chem; 2002 Mar; 7(3):249-59. PubMed ID: 11935349
[TBL] [Abstract][Full Text] [Related]
6. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET.
Lewis JS; Dearling JL; Sosabowski JK; Zweit J; Carnochan P; Kelland LR; Coley HM; Blower PJ
Eur J Nucl Med; 2000 Jun; 27(6):638-46. PubMed ID: 10901449
[TBL] [Abstract][Full Text] [Related]
7. Mixed bis(thiosemicarbazone) ligands for the preparation of copper radiopharmaceuticals: synthesis and evaluation of tetradentate ligands containing two dissimilar thiosemicarbazone functions.
Lim JK; Mathias CJ; Green MA
J Med Chem; 1997 Jan; 40(1):132-6. PubMed ID: 9016338
[TBL] [Abstract][Full Text] [Related]
8. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
9. High purity production and potential applications of copper-60 and copper-61.
McCarthy DW; Bass LA; Cutler PD; Shefer RE; Klinkowstein RE; Herrero P; Lewis JS; Cutler CS; Anderson CJ; Welch MJ
Nucl Med Biol; 1999 May; 26(4):351-8. PubMed ID: 10382836
[TBL] [Abstract][Full Text] [Related]
10. Nitroimidazole-Containing H2dedpa and H2CHXdedpa Derivatives as Potential PET Imaging Agents of Hypoxia with (68)Ga.
Ramogida CF; Pan J; Ferreira CL; Patrick BO; Rebullar K; Yapp DT; Lin KS; Adam MJ; Orvig C
Inorg Chem; 2015 May; 54(10):4953-65. PubMed ID: 25928800
[TBL] [Abstract][Full Text] [Related]
11. Species-dependent binding of copper(II) bis(thiosemicarbazone) radiopharmaceuticals to serum albumin.
Mathias CJ; Bergmann SR; Green MA
J Nucl Med; 1995 Aug; 36(8):1451-5. PubMed ID: 7629593
[TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceuticals Labelled with Copper Radionuclides: Clinical Results in Human Beings.
Follacchio GA; De Feo MS; De Vincentis G; Monteleone F; Liberatore M
Curr Radiopharm; 2018; 11(1):22-33. PubMed ID: 29231149
[TBL] [Abstract][Full Text] [Related]
13. Copper complexes with dissymmetrically substituted bis(thiosemicarbazone) ligands as a basis for PET radiopharmaceuticals: control of redox potential and lipophilicity.
Brown OC; Baguña Torres J; Holt KB; Blower PJ; Went MJ
Dalton Trans; 2017 Oct; 46(42):14612-14630. PubMed ID: 28703233
[TBL] [Abstract][Full Text] [Related]
14. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals.
Maurer RI; Blower PJ; Dilworth JR; Reynolds CA; Zheng Y; Mullen GE
J Med Chem; 2002 Mar; 45(7):1420-31. PubMed ID: 11906283
[TBL] [Abstract][Full Text] [Related]
15. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).
Lewis JS; Herrero P; Sharp TL; Engelbach JA; Fujibayashi Y; Laforest R; Kovacs A; Gropler RJ; Welch MJ
J Nucl Med; 2002 Nov; 43(11):1557-69. PubMed ID: 12411560
[TBL] [Abstract][Full Text] [Related]
16. Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET.
Green MA; Klippenstein DL; Tennison JR
J Nucl Med; 1988 Sep; 29(9):1549-57. PubMed ID: 3261785
[TBL] [Abstract][Full Text] [Related]
17. Validation of 64Cu-ATSM damaging DNA via high-LET Auger electron emission.
McMillan DD; Maeda J; Bell JJ; Genet MD; Phoonswadi G; Mann KA; Kraft SL; Kitamura H; Fujimori A; Yoshii Y; Furukawa T; Fujibayashi Y; Kato TA
J Radiat Res; 2015 Sep; 56(5):784-91. PubMed ID: 26251463
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model.
Young H; Carnochan P; Zweit J; Babich J; Cherry S; Ott R
Eur J Nucl Med; 1994 Apr; 21(4):336-41. PubMed ID: 8005157
[TBL] [Abstract][Full Text] [Related]
19. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
20. Transfer of copper between bis(thiosemicarbazone) ligands and intracellular copper-binding proteins. insights into mechanisms of copper uptake and hypoxia selectivity.
Xiao Z; Donnelly PS; Zimmermann M; Wedd AG
Inorg Chem; 2008 May; 47(10):4338-47. PubMed ID: 18412332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
